Homology Medicines (Homology Medicines) 3-Year EBITDA Growth Rate : 15.90% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Homology Medicines 3-Year EBITDA Growth Rate?

Homology Medicines's EBITDA per Share for the three months ended in Dec. 2023 was $-2.92.

During the past 3 years, the average EBITDA Per Share Growth Rate was 15.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Homology Medicines was 15.90% per year. The lowest was -67.40% per year. And the median was 2.20% per year.

Competitive Comparison of Homology Medicines's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Homology Medicines's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Homology Medicines's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Homology Medicines's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Homology Medicines's 3-Year EBITDA Growth Rate falls into.

Homology Medicines 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Homology Medicines (NAS:FIXX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Homology Medicines 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Homology Medicines's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Homology Medicines (Homology Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (NAS:FIXX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

35H:Germany

Address

One Patriots Park, Bedford, MA, USA, 01730

Website

https://www.homologymedicines.com

Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Executives

Paul Alloway	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
Albert Seymour	officer: Chief Scientific Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Julie Jordan	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Michael Lee Blum	officer: Chief Commercial Officer	C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730
W Bradford Smith	officer: CFO, Treasurer & Secretary	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Arthur Tzianabos	director, officer: President & CEO	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Timothy P Kelly	officer: See Remarks	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Gabriel Cohn	officer: Chief Medical Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Kush Parmar	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures Iv, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: *Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Alise Reicin	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Siyamak Rasty	officer: Chief Operating Officer	C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109